Isomer Partners LP, a Delaware limited partnership (hereinafter “Isomer,” “we,” “us,” “our” or the “Firm”) has its principal place of business in New York, New York. We are an affiliate of the following entities: Isomer Partners GP LLC, a Delaware limited liability company, the general partner of the Firm (the “General Partner”), and Isomer Partners Fund GP LLC, a Delaware limited liability company, the general partner of the Master Fund and the Onshore Fund, each defined below (the “Fund General Partner”). Mendel Hui, the Managing Partner and Chief Investment Officer of the Firm (the “Chief Investment Officer”), is the majority beneficial owner of Isomer and directs the investment activities and operations of the Funds (as defined below). Mr. Hui founded Isomer Partners in January 2016. We serve as the investment adviser, with discretionary trading authority, to private, pooled investment vehicles, the securities of which are offered through a private placement memorandum to US investors that are accredited investors, as defined under the Securities Act of 1933 (the “Securities Act”). We do not tailor our advisory services to the individual needs of any particular investor, and investors cannot impose restrictions on investing in certain securities or types of securities. Isomer manages the following private, pooled investment vehicles:
• Isomer Cayman Fund Ltd., a Cayman Islands exempted company (the “Offshore Fund”);
• Isomer Fund LP, a Delaware limited partnership (the “Onshore Fund”); and
• Isomer Master Fund LP, a Cayman Islands exempted limited partnership (the “Master Fund”). The Offshore Fund and the Onshore Fund invest all of their investable assets in the Master Fund. The Master Fund, Onshore Fund and Offshore Fund are herein collectively referred to as the “Funds.” The Funds, together with any other account Isomer may manage, will be referred to herein as the “Clients.” The Onshore Fund and Offshore Fund are collectively referred to as the “Feeder Funds.” The Onshore Fund’s “Limited Partners” and the Offshore Fund’s “Shareholders” are hereafter collectively referred to

as the “Investors” where appropriate. Our investment decisions and advice with respect to each Fund is to each Fund’s investment objectives and guidelines, as set forth in its respective confidential offering memorandum and governing documents (collectively, “Offering Documents”). This Brochure generally includes information about Isomer and its relationships with its Clients and affiliates. While much of this Brochure applies to all such Clients and affiliates, certain information included herein applies to specific Clients or affiliates only. This Brochure does not constitute an offer to sell, or solicitation of an offer to buy, any securities. The securities of the Funds are offered and sold on a private placement basis under exemptions promulgated under the Securities Act of 1933, as amended (the “Securities Act”), and other exemptions of similar import under U.S. state laws and the laws of other jurisdictions where any offering may be made. Shares in the Offshore Fund are offered on a private placement basis to U.S. tax-exempt entities, and, in accordance with Regulation S of the Securities Act, with respect to non-U.S. persons, and subject to certain other conditions, which are fully set forth in its Offering Documents. The interests in the Onshore Fund are offered on a private placement basis pursuant to Section 3(c)(7) of the Investment Company Act of 1940, as amended (the “Company Act”), to persons who are “accredited investors” as defined under the Securities Act and, if applicable, “qualified purchasers” as defined under the Company Act, and subject to certain other conditions, which are set forth in each Fund’s Offering Documents. Persons reviewing this Brochure should not construe this as an offer to sell or solicitation of an offer to buy the securities of any of the Funds described herein. Any such offer or solicitation will generally be made only by means of a confidential memorandum. We do not currently participate in any Wrap Fee Programs. As of December 31, 2023, Isomer managed Regulatory Assets Under Management (“RAUM”) of approximately $270,046,693 on a discretionary basis.